BioCentury
ARTICLE | Product Development

Setback for Sanofi/GSK COVID-19 vaccine highlights importance of portfolio strategy

December 12, 2020 12:52 AM UTC

A delay in the development of Sanofi and GSK’s COVID-19 vaccine due to a lack of efficacy in older adults reinforces the importance of the portfolio strategy governments are taking in procuring a COVID-19 vaccine. 

Partners Sanofi (Euronext:SAN; NASDAQ:SNY) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced Friday that regulatory submissions for its COVID-19 vaccine would be delayed by about six months after Phase I/II data showed the vaccine did not provide adequate neutralizing antibody titers in adults >60 years old...